Starboard seeks probe after former Pfizer execs pull support for its campaign
Starboard Value has asked Pfizer to set up a special committee to investigate allegations that two of its former senior executives were forced to publicly declare support for CEO Albert Bourla, the hedge fund said on Thursday.
Pfizer's CEO gains support of ex-execs amid activist investor talks
"We have decided not to be involved in the efforts of Starboard Value regarding Pfizer. We are fully supportive of Pfizer Chairman & CEO Albert Bourla, senior management and the board, and we are confident that over time they will deliver shareholder value," the two wrote, in a statement issued on behalf of them by Guggenheim Securities.
Pfizer CEO gains support amid Starboard's activist campaign
Former Pfizer (PFE) executives have rescinded their support of activist investor Starboard Value as it seeks to turn around the struggling pharmaceutical company. Former CEO Ian Read and former CFO Frank D'Amelio are instead putting their full weight behind Pfizer CEO Albert Bourla and Pfizer's board,
Pfizer’s stock dips after two former execs say they won’t support Starboard, offer backing for CEO Albert Bourla
Pfizer Inc.’s stock dipped early Thursday after two of its former executives said they would not support an effort by activist shareholder Starboard Value to orchestrate a turnaround. “We have decided not to be involved in the efforts of Starboard Value regarding Pfizer,
Pfizer chief Albert Bourla to meet activist investor Starboard
Pfizer chief executive Albert Bourla plans to meet Starboard Value, said people familiar with the matter, as the activist investor’s $1bn stake in the pharmaceutical group puts pressure on its board to revive its share price.
Former Pfizer CEO, finance chief step back from Starboard's activist campaign
The about face comes as the board grapples with the activist’s efforts, and just days before Starboard’s Jeff Smith was slated to meet with the CEO, sources said.
Pfizer CEO Bourla to meet with activist investor Starboard Value on turnaround pitch: FT
With Pfizer’s revenue and share price slumping after the drugmaker skyrocketed to new heights during the pandemic, the company’s executives will reportedly hear out activist investor Starboard Valu | Activist investor Starboard Value recently picked up a $1 billion stake in the drugmaker and will now pitch a strategy shift to top executives,
Pfizer CEO plans to meet activist investor Starboard, FT reports
Pfizer CEO Albert Bourla plans to meet key executives of activist hedge fund Starboard Value next week, the Financial Times reported on Tuesday, citing people familiar with the matter.
Pfizer’s Ex-CEO Won’t Be Involved in Starboard Value Effort
Former Pfizer Inc. executives Ian Read and Frank D’Amelio have decided “not to be involved” in Starboard Value’s activist campaign against the drug company, according to a statement released on their behalf late Wednesday.
Ex-Pfizer Top Execs Won’t Join Starboard’s Activist Campaign
Two former Pfizer top executives won’t participate in an activist investor’s effort to pressure the drugmaker to make changes to improve its performance.
Former Pfizer executives pull out of activist investor Starboard’s campaign
Former chief executive and chair Ian Read and former finance chief Frank D’Amelio have decided not to be involved in Starboard’s campaign targeting the drugmaker, they said in a statement on Wednesday.
Pfizer threatened to sue renegade executives prior to activist schism, Starboard's Smith says
Starboard’s Jeff Smith called on the company to assemble a special committee to investigate the matter, describing it as ...
Pfizer CEO Albert Bourla expected to meet with activist Starboard next week - FT
CEO Albert Bourla is expected to meet with activist investor Starboard Value next week after the activist accumulated a $1 ...
What's Going On With Pfizer Stock On Thursday?
On Thursday, Starboard Value LP, a significant shareholder of Pfizer Inc. (NYSE:PFE), issued a letter to the company’s Board ...
Why Pfizer Stock Popped Today
Pfizer ( PFE 3.46%) was a stock on the move Wednesday, and not because of any news generated by the healthcare company.